Abstract
Despite aggressive approaches, including second transplant, donor lymphocyte infusion and several new agents, the prognosis of acute lymphoid leukemia (ALL) patients relapsing after stem-cell transplantation (SCT) remains poor. Monoclonal-antibodies (moAb) could provide a useful tool in this setting. In particular, anti-CD52 moAb is useful in lymphoid malignancies. We thus treated as compassionate with campath-1H 3 ALL patients relapsed after SCT. In 2 cases we observed a reduction of peripheral blood and/or bone marrow blasts. In 1 case a GVHD grade reduction was observed. Larger trials are required in order to define the role of campath-1H in ALL.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Alemtuzumab
-
Antibodies, Monoclonal / pharmacology
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neoplasm / pharmacology
-
Antibodies, Neoplasm / therapeutic use*
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use
-
Drug Evaluation
-
Female
-
Graft vs Host Disease / drug therapy*
-
Hematopoietic Stem Cell Transplantation / adverse effects*
-
Humans
-
Male
-
Middle Aged
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
-
Recurrence
-
Salvage Therapy / methods
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neoplasm
-
Antineoplastic Agents
-
Alemtuzumab